Details for Patent: 10,265,293
✉ Email this page to a colleague
Which drugs does patent 10,265,293 protect, and when does it expire?
Patent 10,265,293 protects SYNDROS and is included in one NDA.
Summary for Patent: 10,265,293
| Title: | Oral cannabinoid formulations |
| Abstract: | Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. |
| Inventor(s): | Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill |
| Assignee: | Wellhouse Pharma LLC |
| Application Number: | US15/132,896 |
|
Patent Claim Types: see list of patent claims | Formulation; Delivery; |
Drugs Protected by US Patent 10,265,293
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellhouse Pharma | SYNDROS | dronabinol | SOLUTION;ORAL | 205525-001 | Mar 23, 2017 | DISCN | Yes | No | 10,265,293 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
